Skip to main content
. 2021 Dec 13;4(12):e2138550. doi: 10.1001/jamanetworkopen.2021.38550

Figure 1. Prognostic Significance of the Prostate-Specific Membrane Antigen Nomogram in the Multi-institutional Cohort.

Figure 1.

A, Concordance indices of the nomogram for biochemical recurrence (BCR), distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall survival (OS) at 3 to 10 years. Error bars are 95% CIs. B-E, Survival curves (freedom from BCR, freedom from DM, freedom from PCSM, and OS) according to nomogram-defined risk groups, corresponding to upstaging risks of 14% or less (group 1), 14.1% to 27% (group 2), 27.1% to 41% (group 3), and greater than 41% (group 4).